WGS GeneDx Holdings Corp.companySEC Filings & Insider Trading Activity 2026
Latest GeneDx Holdings Corp. (WGS) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 23, 2026, a 10-Q quarterly report filed on October 28, 2025, an 8-K current report filed on March 2, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for GeneDx Holdings Corp. (WGS) (SEC CIK 1818331), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
- • New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
Risk Factors
- • Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
- • Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
Management Discussion & Analysis
- • Revenue and profitability details not provided in the excerpt
- • No segment performance data disclosed
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New regulatory risk: FDA final rule on lab-developed tests (LDTs) overturned March 31, 2025, creates ongoing uncertainty for LDT compliance
- • Most material regulatory update: Potential enforcement of FDA oversight on LDTs could increase costs and reduce revenue, impacting financial condition
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Filing signed March 2, 2026 by CEO Katherine Stueland, confirming a new Loan Agreement (Term Loan) is material enough to trigger 8-K disclosure
- • Term Loan proceeds use is referenced but specific amount, rate, and maturity not disclosed in this section — key terms likely in full exhibit
Item 2.02: Results of Operations and Financial Condition
- • Full-year 2025 financial results announced Feb 23, 2026 via press release and earnings presentation
- • Key figures in Exhibits 99.1 (press release) and 99.2 (earnings presentation) — primary source for revenue, margins, and guidance
Annual Reports Archive10-K
AI-powered analysis of GeneDx Holdings Corp. (WGS) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of GeneDx Holdings Corp. (WGS) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of GeneDx Holdings Corp. (WGS) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $202.6M | $305.4M | $427.5M |
| Gross Profit | — | $90.0M | $194.4M | $298.2M |
| Operating Income | — | -$180.6M | -$23.2M | -$13.1M |
| Net Income | -$549.0M | -$175.8M | -$52.3M | -$21.0M |
| Gross Margin | — | 44.4% | 63.6% | 69.7% |
| Op. Margin | — | -89.2% | -7.6% | -3.1% |
| Net Margin | — | -86.8% | -17.1% | -4.9% |
| Balance Sheet | ||||
| Total Assets | — | $418.8M | $419.4M | $523.7M |
| Equity | $253.7M | $228.0M | $245.2M | $308.2M |
| ROE | -216.4% | -77.1% | -21.3% | -6.8% |
Source: XBRL financial data from GeneDx Holdings Corp. (WGS) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Feb 23, 2026 | — | Analysis | — |
10-K | Feb 23, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Oct 28, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 29, 2025 | Jun 30, 2025 | — | |
10-Q | Apr 30, 2025 | Mar 31, 2025 | — | |
10-K | Feb 20, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 29, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 30, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 29, 2024 | Mar 31, 2024 | — | |
10-K | Feb 23, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 14, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 15, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 14, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 15, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 21, 2021 | Jun 30, 2021 | — | |
10-Q | May 24, 2021 | Mar 31, 2021 | — | |
10-K | Mar 30, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 16, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest WGS SEC filings in 2026?
GeneDx Holdings Corp. (WGS) has filed a 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 28, 2025, an 8-K current report on March 2, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did WGS file its most recent 10-K annual report?
GeneDx Holdings Corp. (WGS) filed its most recent 10-K annual report on February 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view WGS 10-Q quarterly reports?
GeneDx Holdings Corp. (WGS)'s most recent 10-Q quarterly report was filed on October 28, 2025. SignalX displays every WGS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has WGS filed recently?
GeneDx Holdings Corp. (WGS)'s most recent 8-K was filed on March 2, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find WGS insider trading activity (Form 4)?
SignalX aggregates every WGS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does WGS file with the SEC?
GeneDx Holdings Corp. (WGS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new WGS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GeneDx Holdings Corp. (WGS).
What is WGS's SEC CIK number?
GeneDx Holdings Corp. (WGS)'s SEC CIK (Central Index Key) number is 1818331. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1818331 to look up all WGS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find WGS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from GeneDx Holdings Corp. (WGS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of GeneDx Holdings Corp. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 25+ filings.